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HIV Infection and the Risk of World Health
Organization–Defined Sudden Cardiac
Death
Matthew S. Freiberg , MD, MSc; Meredith S. Duncan , PhD; Charles Alcorn, BS; Chung-Chou H. Chang, PhD;
Suman Kundu , DSc, MSc; Asri Mumpuni, MPH; Emily K. Smith , MPH; Sarah Loch , MPH;
Annie Bedigian, BS; Eric Vittinghoff , PhD; Kaku So-Armah, PhD; Priscilla Y. Hsue , MD;
Amy C. Justice, MD, PhD; Zian H. Tseng, MD, MAS
BACKGROUND: People living with HIV have higher sudden cardiac death (SCD) rates compared with the general population.
Whether HIV infection is an independent SCD risk factor is unclear.

Downloaded from http://ahajournals.org by on September 15, 2021

METHODS AND RESULTS: This study evaluated participants from the Veterans Aging Cohort Study, an observational, longitudinal
cohort of veterans with and without HIV infection matched 1:2 on age, sex, race/ethnicity, and clinical site. Baseline for this
study was a participant’s first clinical visit on or after April 1, 2003. Participants were followed through December 31, 2014.
Using Cox proportional hazards regression, we assessed whether HIV infection, CD4 cell counts, and/or HIV viral load were
associated with World Health Organization (WHO)–defined SCD risk. Among 144 336 participants (30% people living with
HIV), the mean (SD) baseline age was 50.0 years (10.6 years), 97% were men, and 47% were of Black race. During follow-up
(median, 9.0 years), 3035 SCDs occurred. HIV infection was associated with increased SCD risk (hazard ratio [HR], 1.14; 95%
CI, 1.04–1.25), adjusting for possible confounders. In analyses with time-varying CD4 and HIV viral load, people living with HIV
with CD4 counts <200 cells/mm3 (HR, 1.57; 95% CI, 1.28–1.92) or viral load >500 copies/mL (HR, 1.70; 95% CI, 1.46–1.98) had
increased SCD risk versus veterans without HIV. In contrast, people living with HIV who had CD4 cell counts >500 cells/mm3
(HR, 1.03; 95% CI, 0.90–1.18) or HIV viral load <500 copies/mL (HR, 0.97; 95% CI, 0.87–1.09) were not at increased SCD risk.
CONCLUSIONS: HIV infection is associated with increased risk of WHO-defined SCD among those with elevated HIV viral load
or low CD4 cell counts.
Key Words: CD4 cell count ■ HIV infection ■ HIV viral load ■ sudden cardiac death

P

eople living with HIV (PLWH) have an increased
risk of acute myocardial infarction,1 ischemic
stroke,2 heart failure,3 pulmonary hypertension,4
and peripheral artery disease5 compared with people
without HIV. The mechanisms driving this excess risk
of cardiovascular disease likely involve HIV-
specific
factors including chronic immune activation and inflammation,6 antiretroviral therapy–
related dyslipidemia,7 and behaviors such as smoking and alcohol
consumption.8 These mechanisms and cardiovascular

disease are also likely risk factors for sudden cardiac
death (SCD).9,10 Whether HIV infection is an independent risk factor for SCD, however, is unclear because
data are sparse.9,11,12 The largest study conducted to
date was our single-site study involving 2860 patients
at an HIV clinic in San Francisco.9 We reported a rate
of SCD among PLWH that was 4.5-fold higher than expected compared with the general population, but our
study did not account for differences in prevalence of
cardiovascular risk factors between groups. Whether
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CLINICAL PERSPECTIVE
What Is New?

• In this national study, people living with HIV infection have an increased risk of sudden cardiac death compared with people living without
HIV infection.
• People living with HIV infection who have unsuppressed viral load or lower CD4 cell counts
are at increased risk of sudden death compared
with people without HIV infection.

What Are the Clinical Implications?

• This study reinforces the need for viral suppression and heart disease risk factor modification
among people living with HIV infection.
• For those who have sustained viremia or low
CD4 cell counts, providers should be aware of
an excess risk of sudden death; compliance
with antiretroviral therapy as well as providing
guideline-
based care for cardiovascular risk
factors is critically important among people living with HIV infection.
• Understanding the mechanism underlying this
excess risk among people living with HIV will be
important for the prevention of sudden cardiac
death in this population.
Downloaded from http://ahajournals.org by on September 15, 2021

Nonstandard Abbreviations and Acronyms
PLWH
SCD
VA
VACS
WHO

people living with HIV
sudden cardiac death
Veterans Affairs
Veterans Aging Cohort Study
World Health Organization

HIV infection confers an excess risk of SCD compared
with a population without HIV that is demographically
and behaviorally similar is unknown.
The objective of this study was to examine the association between HIV and SCD in a large national
cohort of veterans with HIV and demographically and
behaviorally similar veterans without HIV.

METHODS
Because of the sensitive nature of the data collected
for this study, requests to access the data set from
qualified researchers trained in human participant confidentiality protocols may be sent to the VACS (Veterans
Aging Cohort Study) at matthew.s.freiberg@vumc.org.
VACS has been described in detail elsewhere13; it is

a prospective, observational, longitudinal study of veterans with HIV matched 1:2 to veterans without HIV
on age, sex, race/ethnicity, clinical site, and year of
enrollment. Study participants were enrolled using a
previously validated algorithm that leverages the US
Department of Veteran Affairs (VA) national electronic
medical record system. All study data were extracted
from the VA Corporate Data Warehouse or from
Medicare, Medicaid, or VA fee-for-service administrative files. We performed a retrospective analysis of this
prospectively gathered data. Vanderbilt University and
the West Haven VA Medical Center institutional review
boards approved this study. VACS has a waiver of
consent as data are partially deidentified. Specifically,
dates (eg, of hospital encounters and procedures or
death) are available but other identifiers are lacking and
investigators have no way of contacting participants.
Drs Freiberg and Duncan had full access to all of the
data in this study and are responsible for its integrity
and the data analysis.

Study Population
For this analysis, we included all VACS participants
who were alive and enrolled in VACS on or after April
1, 2003. The baseline date for this study was a VACS
participant’s first clinical encounter on or after April 1,
2003. All participants were followed until the first of an
SCD event, other death event, or December 31, 2014.
Consistent with prior work examining SCD, we limited
the participants to those between the ages of 18 to
90 years.10

Independent Variable
HIV infection was determined using a previously
validated algorithm consisting of the presence of at
least one inpatient or two outpatient International
Classification of Diseases, Ninth Revision (ICD-9)
codes for AIDS (042), asymptomatic HIV (V08), and/
or related Diagnostic-Related Group codes (488–490)
and inclusion in the VA immunology case registry.13

Dependent Variable
SCD was defined using an algorithm that was based
on our prior work,9 and combines criteria from the
World Health Organization (WHO) with a comprehensive chart review.14 The WHO criteria for SCD is the following: (1) sudden unexpected death within 1 hour of
symptom onset if witnessed or within 24 hours of being
observed alive and symptom free (unwitnessed).14 For
our protocol, we employed a 4-step process that included: (1) review of each participant’s death certificate, (2) review of administrative data from the VA
and Centers for Medicare and Medicaid Services, (3)
manual review of clinical notes and data closest to the
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date of death that extended up to 1 year before the
date of death within the VA electronic medical record,
and (4) a review of non-VA administrative data assessing whether participants were hospitalized outside the
VA within 1 month of death. The specific algorithm is
presented in Figure 1 and includes both inclusion and
exclusion criteria to identify SCD events. Specific steps
undertaken in the adjudication process are detailed in
Data S1.

Covariates

Downloaded from http://ahajournals.org by on September 15, 2021

All covariates were selected a priori based on clinical judgement and were assessed at baseline by selecting the closest value to the baseline date unless
otherwise noted. Age, sex, and race/ethnicity were
determined using administrative data. As previously
described,1,3,5 clinical outpatient and laboratory data
were used to assess hypertension, diabetes mellitus, hypercholesterolemia, renal disease, body mass
index, and anemia. Smoking was measured from
health factors data15 that were collected in a semistandardized form within the VA electronic medical
record. Hepatitis C infection was defined using a previously validated algorithm including positive hepatitis
C antibody test results or administrative ICD-9 codes
for this diagnosis.16 As we have previously done, prevalent alcohol use disorder, cocaine abuse or dependence, cardiovascular disease, and chronic obstructive
pulmonary disease were assessed using ICD-9 code
data.4 Cardiovascular disease was considered prevalent (ie, present at or before baseline) if a participant
had at least 1 inpatient or 2 outpatient ICD-9 codes
for prior acute myocardial infarction, coronary artery revascularization, ischemic stroke, or heart failure.1,3,5,17 Ever use of QT prolongation medication was
defined as the use of medications associated with QT
prolongation (Table S1) at any point before baseline
through 180 days after baseline. Baseline HIV-specific
variables including CD4 cell counts, HIV viral load
data, and antiretroviral therapy were collected within
180 days on either side of the participant’s baseline
date. For time-updated analyses, we also collected all
measures of CD4 cell count and HIV viral load from
the participant’s baseline date through December
31, 2014. Antiretroviral therapy was categorized as
receipt of any therapy that was available on the VA
formulary (eg, nucleoside reverse transcriptase inhibitor, non-nucleoside reverse transcriptase inhibitor, or
protease inhibitor). We also assessed receipt of any
antiretroviral therapy (same definition as baseline plus
newer medications such as integrase inhibitors) within
180 days of the date of SCD, non-SCD death, or date
of last follow-up. VACS investigators have previously
reported that 96% of veterans with HIV obtain their
antiretroviral therapies from the VA.13

Association of HIV With Sudden Cardiac Death

Missing Data
For this investigation, we used multivariate imputation
by chained equation techniques that generated 5 complete data sets to handle missing covariate data while
maintaining the correlation structure. For continuous
variables, regression-based predictive mean matching
was utilized to produce biologically plausible imputed
values while the discriminant function with a noninformative Jeffreys prior was used to impute categorical
variables.18,19 Results across imputed data sets were
combined according to Rubin rules.20

Statistical Analysis
Descriptive statistics for all variables by HIV status
were compared using χ2 test or Fisher exact test for
categorical variables and Wilcoxon rank sum test for
continuous variables. We calculated SCD incidence
rates per 100 000 person-years stratified first by HIV
status, next by baseline HIV viral load and CD4 cell
count, and then decade age group. We additionally
plotted cumulative SCD incidence by HIV status. We
constructed 3 sets of Cox proportional hazard regression models to assess SCD risk and estimate hazard
ratios (HRs) and corresponding 95% CIs for the following groups compared with those without HIV: (1)
PLWH as a whole; (2) PLWH with CD4 ≥500, PLWH
with 200≤CD4<500, and PLWH with CD4 <200; and
(3) PLWH with a viral load <500 and PLWH with a viral
load ≥500. In each set of models we performed a minimally adjusted regression that included age, sex, race/
ethnicity, and prevalent CVD as covariates, as well
as multivariable-adjusted models that additionally included hypertension, diabetes mellitus, low-and high-
density lipoprotein cholesterol, triglycerides, hepatitis
C infection, smoking status, renal disease, body mass
index, anemia, cocaine dependence or abuse, alcohol
dependence or abuse, chronic obstructive pulmonary
disease, and use of QT prolongation medications as
covariates. For these multivariable-
adjusted primary
models, we repeated the analysis using HIV viral load
and/or CD4 cell count data as time-varying covariates
such that each participant contributed person-time to
the CD4 cell count or HIV viral load category reflecting
their status at each biomarker assessment For example, if a PLWH had 3 years of follow-up with a CD4 cell
count of 250 cells/mm3 at baseline, 300 cells/mm3 at
6 months, and 550 cells/mm3 at 1.5 years, they would
contribute 0 to 1.5 years of their follow-up time to the
200≤CD4<500 cells/mm3 group, and 1.5 to 3 years to
the CD4 ≥500 cells/mm3 group. For individuals who
experienced SCD, the death contributed to the group
in which the participant held membership on the date
of death. From the multivariable-adjusted models with
HIV status (yes/no) as the primary exposure of interest, we also plotted the adjusted cumulative SCD

J Am Heart Assoc. 2021;10:e021268. DOI: 10.1161/JAHA.121.0212683

Freiberg et al

Association of HIV With Sudden Cardiac Death

Downloaded from http://ahajournals.org by on September 15, 2021
Figure 1. Sudden cardiac death (SCD) adjudication and sample derivation.
CMS indicates Centers for Medicare and Medicaid Services; DNI, do not intubate; DNR, do not resuscitate;
ED, emergency department; and VACS, Veterans Aging Cohort Study.
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incidence by HIV status. Because the prevalence of
cigarette smoking was higher in our sample than in the
general population, we performed a sensitivity analysis
in which we limited the sample to never-smokers and
reassessed the association between HIV status and
SCD.
Cox proportional hazards regression models were
then stratified by HIV status to assess SCD risk factors;
CD4 cell count and HIV viral load were time-varying in
models restricted to PLWH. We then assessed SCD
risk stratified by HIV status across a set of SCD risk
factors identified from the previous models (prevalent
CVD, hypertension, current smoking, hepatitis C infection, anemia, alcohol use disorder, chronic obstructive
pulmonary disease) by calculating the incidence rate
per 100 000 person-years and HRs compared with
those with 0 risk factors. Incidence rates and HRs were
adjusted for age, sex, race/ethnicity, CD4 cell count
(PLWH only), and HIV viral load (PLWH only). Incidence
rates were estimated using Poisson regression assuming the number of SCD risk factors was a categorical
variable, while in Cox proportional hazards regression
models the number of SCD risk factors was modeled
using restricted cubic splines with 3 knots. The spline
was tested for departure from linearity via a likelihood
ratio test. The proportional hazards assumption was
not violated for the main predictor (HIV infection status)
using the log-log survival plot. Although the full VACS
cohort is matched, matching was not preserved following exclusions, thus analyses did not account for
matching. A 2-sided P value of <0.05 was used to determine statistical significance, and all analyses were
performed using SAS version 9.4 (SAS Institute Inc).

RESULTS
Participant Characteristics
This analysis included 144 336 participants (43 407
[30%] were veterans with HIV) at baseline. The median age of participants at baseline was 50 years and
the majority were men and either Black or White participants (Table 1). Veterans without HIV had a higher
prevalence of hypertension, diabetes mellitus, elevated
low-
density lipoprotein cholesterol, obesity, alcohol
use disorders, chronic obstructive pulmonary disease,
and cardiovascular diseases than veterans with HIV
but lower prevalence of low high-density lipoprotein
cholesterol, elevated triglycerides, current smoking,
hepatitis C infection, and history of cocaine abuse and
dependence (Table 1). At baseline, among veterans
with HIV, the median CD4 cell count was 385 cells/
mm3 and median HIV type 1 RNA was 999 copies/
mL; 39.5% were taking antiretroviral therapy. Within
180 days of the date of last follow-up, 72.6% of veterans with HIV were taking antiretroviral therapy.

Association of HIV With Sudden Cardiac Death

Unadjusted SCD Incidence Rates
During a median follow-up of 9.0 years, 3035 SCDs
occurred, with 777 (26%) in veterans with HIV.
Unadjusted SCD rates per 100 000 person-
years
for veterans with HIV and veterans without HIV were
232 (95% CI, 215–249) and 234 (95% CI, 224–246),
respectively (Table 2). SCD rates increased with increasing decade of age for both veterans with HIV
and those without HIV but there was no difference by
HIV status within age groups (Table 3). For veterans
with HIV, SCD rates also increased with decreasing
baseline CD4 cell counts and increasing HIV viral load
(Table 2).

Adjusted SCD Risk by HIV Status and
Measures of HIV Control
Compared with veterans without HIV, veterans with
HIV had a 14% increase in SCD risk after adjusting
for confounders (Table 2 and Figure 2). This risk was
29% higher among veterans with HIV who had baseline CD4 cell counts <200 cells/mm3, and 17% higher
among veterans with HIV with a baseline HIV viral load
≥500 copies/mL, both compared with veterans without HIV (Table 2).
In analyses with time-varying viral load and CD4 cell
counts (the median number of counts for both tests
during follow-up were 12 per participant), CD4 cell
counts <200 cells/mm3 in veterans with HIV was associated with a 57% (HR, 1.57; 95% CI, 1.28–1.92) increased risk of SCD compared with veterans without
HIV (Table 2). Similarly, HIV viral loads >500 copies/
mL among veterans with HIV was associated with a
70% (HR, 1.70; 95% CI, 1.46–1.98) increased risk of
SCD compared with veterans without HIV (Table 2).
In contrast, time-varying CD4 cell counts >500 cells/
mm3 and HIV viral loads <500 copies/mL in veterans with HIV were not associated with an increased
risk of SCD as compared with veterans without HIV
(Table 2).
In our sensitivity analysis limited to never-smokers,
we observed that HIV infection was associated with
a 41% increased risk of SCD (HR, 1.41; 95% CI, 1.13–
1.76) after multivariable adjustment.

SCD Risk Factors by HIV Status
Among veterans with HIV, age, male sex, cardiovascular disease, hypertension, current smoking, hepatitis
C infection, increasing body mass index, anemia, alcohol use disorder and chronic obstructive pulmonary
disease were all associated with higher risk of SCD
(P<0.05 for all, Table 4). These risk factors, plus elevated low-density lipoprotein cholesterol and diabetes
mellitus, were also associated with SCD among veterans without HIV.
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Table 1. Baseline Characteristics of VACS Participants
Stratified by HIV Status
Veterans
with HIV
(n=43 407)

Veterans
without HIV
(n=100 929)

Mean (SD)

49.2 (10.7)

50.1 (10.6)

Median

49.0
97.2

Baseline characteristic*
Age, y

Men, %

Table 1. Continued

Baseline characteristic*
History of alcohol abuse, %

Veterans
with HIV
(n=43 407)

Veterans
without HIV
(n=100 929)

25.7

26.4

History of cocaine abuse, %

18.9

14.5

11.2

12.2

50.0

Chronic obstructive pulmonary
disease, %

97.2

QT prolongation medication, %

57.0

45.0

HIV-specific variables

Race/ethnicity, %

‡

CD4 cell count, cells/mm3†

Black

48.0

47.0

White

39.8

40.0

Mean (SD)

428.1 (296.7)

…

8.5

Median

385.0

…

Mean (SD)

66 455.2
(308 687.7)

…

Median

999.0

…

Nucleoside reverse transcriptase
inhibitor+protease inhibitor

17.1

…

Nucleoside reverse transcriptase
inhibitor+nonnucleoside reverse
transcriptase inhibitor

13.0

…

Other combinations

9.4

…

No antiretroviral therapy

60.5

…

Hispanic
Other

7.9

§

History of CVD, %

†

HIV type 1 RNA, copies/mL

4.4

4.5

13.7

17.7

Cardiovascular risk factors, %
Hypertension†
None

43.1

29.5

Controlled

31.7

38.7

Uncontrolled

25.2

31.8

Diabetes mellitus

11.4

19.1

47.9

36.1

Lipids, mg/dL†
LDL-C <100
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LDL-C 100–129

29.4

32.5

LDL-C 130–159

15.5

20.6

LDL-C ≥160

7.2

10.8

HDL-C ≥60

11.6

14.0

HDL-C 40–59

38.0

46.9

HDL-C <40

50.4

39.1

Triglycerides ≥150

45.2

38.3

Current

55.0

49.2

Former

16.4

18.9

Never

28.6

31.9

Negative

65.0

63.1

Positive

29.0

13.6

Never tested

6.0

23.4

eGFR ≥60

91.6

92.8

eGFR <60

8.4

7.2

Mean (SD)

25.8 (4.9)

29.5 (6.1)

Median

25.2

28.8

Hemoglobin ≥14

54.1

70.4

Smoking, %†

Other risk factors, %
Hepatitis C infection, %

Renal disease, mL/min per 1.73 m

2†

Antiretroviral therapy, %

SI conversion factors: to convert high-
density lipoprotein cholesterol
(HDL-C) and low-density lipoprotein cholesterol (LDL-C) to millimoles per
liter, multiply by 0.0259; hemoglobin to grams per liter, multiply by 10;
and triglycerides to millimoles per liter, multiply by 0.0113. CVD indicates
cardiovascular disease; and VACS, Veterans Aging Cohort Study.
*All characteristics were statistically different among veterans with and
without HIV (P<0.05) using χ2 test or Wilcoxon rank sum test except sex
(P=0.51).
†
All variables had complete data except the following: hypertension
data were available on 42 741 (people living with HIV [PLWH]) and 96 489
(uninfected); LDL-
C data were available on 34 991 (PLWH) and 80 304
(uninfected); HDL-
C data were available on 35 469 (PLWH) and 81 108
(uninfected); triglyceride data were available for 36 012 (PLWH) and 81 022
(uninfected); smoking data were available on 30 304 (PLWH) and 72 244
(uninfected); hepatitis C infection data were available on 43 249 (PLWH)
and 100 593 (uninfected); estimated glomerular filtration rate (eGFR) data
were available on 40 857 (PLWH) and 90 488 (uninfected); body mass index
(BMI) data were available on 41 716 (PLWH) and 94 141 (uninfected); anemia
data were available on 41 173 (PLWH) and 89 540 (uninfected); CD4 cell
count data were available on 35 219 (PLWH); and HIV type 1 RNA data were
available on 35 177 (PLWH).
‡
Because veterans without HIV do not have HIV-specific biomarkers or
antiretroviral therapy regimens, these cells contain only dashes.
§
Other includes American Indian/Alaska Native, Asian, Native Hawaiian/
Pacific Islander, Decline to Answer/Unknown.

BMI, kg/m2†

Anemia, g/dL†

Hemoglobin 12–13.9

32.4

24.8

Hemoglobin 10–11.9

10.5

4.0

Hemoglobin <10

3.0

0.7

(Continued)

In both veterans with and without HIV, the rates
and risk of SCD increased with increasing number
of SCD risk factors (Figure 3). For those with no risk
factors, SCD rates were low (Figure 3). The association between log-
hazards of SCD and number
of SCD risk factors did not significantly differ from
linearity among veterans with HIV, but was nonlinear among veterans without HIV (test for departure
from linearity: P valueveterans without HIV infection=0.003; P
valueveterans with HIV=0.26). When assuming a log-linear
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Table 2. Rates and Risk of SCD by HIV Status

Group

SCD
events*

No.*

Rate per 100 000
PY (95% CI)*,†

Minimally
adjusted SCD
risk (95% CI)†

Adjusted SCD
risk (95% CI)‡

Adjusted SCD risk
with time-varying HIV
biomarkers (95% CI)§

Stratified by HIV status
HIV−

43 407

2258

234 (224–246)

1.00

1.00

…

HIV+

100 929

777

232 (215–249)

1.00 (0.92–1.08)

1.14 (1.04–1.25)

…

Stratified by HIV status and CD4 cell count
HIV−

100 929

2258

235 (224–246)

1.00

1.00

1.00

HIV+, CD4 ≥500

12 308

214

222 (194–254)

0.96 (0.83–1.11)

1.09 (0.95–1.26)

1.03 (0.90–1.18)

HIV+, 200 ≤CD4<500

14 592

256

219 (194–248)

0.96 (0.85–1.09)

1.13 (0.99–1.28)

1.11 (0.96–1.28)

HIV+, CD4 <200

8319

144

259 (220–305)

1.13 (0.95–1.34)

1.29 (1.07–1.56)

1.57 (1.28–1.92)

8188

163

245 [210–287]

…

…

…

HIV+, missing CD4

‖

Stratified by HIV status and viral load
HIV−

100 929

2258

235 [224, 246]

1.00

1.00

1.00

HIV+, VL <500

16 147

303

220 [196, 246]

0.97 [0.87, 1.08]

1.12 [1.00, 1.26]

0.97 [0.87, 1.09]

HIV+, VL ≥500

19 031

312

238 [213, 266]

1.03 [0.92, 1.15]

1.17 [1.04, 1.31]

1.70 [1.46, 1.98]

HIV+, missing VL‖

8230

162

243 [208, 284]

…

…

…

PY indicates person-years; and SCD, sudden cardiac death.
*Values correspond to the analysis using baseline values of CD4 and HIV viral load, not the time-updated analysis.
†
Adjusted for age, sex, race/ethnicity, and prevalent cardiovascular disease (CVD).
‡
Adjusted for age, sex, race/ethnicity, hypertension, diabetes mellitus, low-and high-density lipoprotein cholesterol, triglycerides, hepatitis C infection,
smoking status, renal disease, body mass index, anemia, cocaine dependence or abuse, alcohol dependence or abuse, chronic obstructive pulmonary
disease, use of QT prolongation medications, and prevalent CVD.
§
Adjusted for all factors in (‡) but CD4 and viral load are time updated.
‖
Missing category used only for calculation of incidence rates. For models, missing CD4 cell counts were imputed.
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association between number of risk factors and risk
of SCD we observed that among veterans with HIV,
SCD risk increased by 1.49-fold (95% CI, 1.40–1.58)
for each additional SCD risk factor. As there was a
significantly nonlinear association between number
of risk factors and risk of SCD in veterans without
HIV infection, there is not a single summary measure to report that describes the increase in SCD

risk per additional SCD risk factor; the association is
depicted in panel B of Figure 3.

DISCUSSION
In VACS, veterans with HIV had an increased risk of
WHO-
defined SCD compared with veterans without HIV when the virus was not suppressed or when

Table 3. Rates of SCD Per 100 000 Person-Years by Decade of Age and HIV Status
Age group, y
Statistic

<30

30– 39

40– 49

50– 59

60– 69

70–79

80– 89

Participants, n

3766

10 986

32 921

36 635

12 614

3439

568

SCDs, n

5

53

629

1086

336

130

19

58 (44–75)

215 (199–233)

366 (344–388)

410 (369–456)

577 (486–685)

671 (428–1052)

Uninfected

SCD rates per
25 (10–59)
100 000 PY (95% CI)
HIV infected
Participants, n

1886

5433

14 622

14 933

5048

1295

190

SCDs, n

2

25

248

340

121

37

4

SCD rates per
19 (5–77)
100 000 PY (95% CI)

57 (39–85)

212 (187–240)

326 (293–363)

428 (358–511)

525 (380–724)

519 (195–1382)

Incidence rate ratio
(95% CI)

0.99 (0.62–1.60)

0.98 (0.85–1.14)

0.89 (0.79–1.01) 1.04 (0.85–1.28)

0.91 (0.63–1.31)

0.77 (0.26–2.27)

0.78 (0.15–4.02)

PY indicates person-years; and SCD, sudden cardiac death.
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Figure 2. Multivariable-adjusted cumulative sudden cardiac death (SCD) incidence by HIV status.
Adjusted incidence output from a Cox proportional hazards regression model adjusted for age, sex, race/
ethnicity, hypertension, diabetes mellitus, low-and high-density lipoprotein cholesterol, triglycerides,
hepatitis C infection, smoking status, renal disease, body mass index, anemia, cocaine dependence or
abuse, alcohol dependence or abuse, chronic obstructive pulmonary disease, use of QT prolongation
medications, and prevalent cardiovascular disease. PLWH indicates people living with HIV.

CD4 cell counts were low. Traditional cardiovascular
disease risk factors, hepatitis C infection, alcohol use
disorder, anemia, and chronic obstructive pulmonary
disease were also associated with an increased risk
of SCD regardless of HIV status. Among veterans with
HIV, the risk of SCD increased by 49% with each additional SCD risk factor.
To our knowledge, this is the largest study to date
reporting that PLWH have an excess risk of SCD and
the only national study to compare PLWH with a demographically and behaviorally (eg, substance use and
abuse) similar uninfected reference population that included adjudicated SCDs. These findings are consistent with earlier reports by our group and others of an
excess risk of SCD among PLWH9,11,12 and extend prior
work by including participants without existing heart
failure and assessing the impact of time-updated viral
load status and immune function over a median follow-up period of 9 years. Notably, the magnitude of
increased SCD risk in HIV-infected versus uninfected
veterans in the current study is substantially lower than
our 2012 study, which compared SCD rates in our
specialty HIV clinic over 10 years with the expected

SCD rate in the uninfected county-wide population.9
As such, the groups in our first study were not demographically and behaviorally similar, and variables
known to increase risk of SCD such as coronary artery disease, smoking, and heart failure were higher in
PLWH. Indeed, a major strength of the current study
is that we accounted for major differences in risk factor prevalence between comparator groups, allowing
us to more accurately estimate the excess risk of SCD
associated with HIV infection. In VACS, this excess risk
of SCD was not initially present in unadjusted analyses
because the uninfected veterans had a higher burden
of SCD risk factors including prevalent cardiovascular
disease.
While the exact mechanism underlying this excess
SCD risk remains unknown, it is likely multifactorial and
linked to both HIV infection and the burden of SCD risk
factors. Prior studies link HIV infection to cardiovascular disease,21 inflammation,6 atrial fibrillation,22 autonomic dysfunction,23 QT prolongation,24 heart failure,3
low ejection fraction,25 and cardiac fibrosis,26 each of
which may play a role in SCD. The latter is present even
among PLWH without ischemic cardiomyopathy26 and
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Table 4. Associations Between Clinical Characteristics
and SCD Among Veterans With and Without HIV Infection

Table 4.

Continued
HR (95% CI)*

HR (95% CI)*

Characteristic

Veterans with
HIV

Veterans
without HIV

Age, 10 y

1.53 (1.39–1.69)

1.31 (1.25–1.38)

Male sex

2.32 (1.03–5.23)

2.86 (1.74–4.70)

Black vs White

0.75 (0.62–0.90)

0.98 (0.90–1.08)

Hispanic vs White

0.52 (0.35–0.77)

0.62 (0.51–0.76)

Other ‡vs White

1.73 (1.16–2.59)

1.22 (0.97–1.52)

1.77 (1.44–2.17)

2.12 (1.93–2.33)

Race/ethnicity

Prevalent CVD
Hypertension
Controlled vs none

1.66 (1.33–2.07)

1.65 (1.43–1.89)

Uncontrolled vs none

1.65 (1.31–2.07)

2.02 (1.76–2.32)

1.23 (0.97–1.55)

1.44 (1.30–1.59)

Diabetes mellitus

Veterans with
HIV

Veterans
without HIV

Nonnucleoside
reverse transcriptase
inhibitor+nucleoside
reverse transcriptase
inhibitor vs no therapy

0.97 (0.77–1.21)

…

Other vs no therapy

0.87 (0.67–1.13)

…

Characteristic

BMI indicates body mass index; CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; HDL-
C, high-
density lipoprotein
cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; and
SCD, sudden cardiac death.
*Models adjusted for all listed characteristics were run separately for
veterans with and without HIV infection.
†
P-value> 0.05.
‡
Other includes American Indian/Alaska Native, Asian, Native Hawaiian/
Pacific Islander, Decline to Answer/Unknown.

Lipids, mg/dL
LDL-C 100–129 vs <100

1.07 (0.86–1.33)

1.03 (0.91–1.16)

LDL-C 130–159 vs <100

1.00 (0.77–1.29)

1.14 (0.99–1.30)

LDL-C ≥160 vs <100

1.38 (1.00–1.92)†

1.32 (1.14–1.53)

HDL-C 40–59 vs ≥60

0.66 (0.50–0.86)

0.81 (0.70–0.93)

HDL-C <40 vs ≥60

0.73 (0.55–0.96)

0.85 (0.73–0.99)

Triglycerides ≥150 vs <150

1.00 (0.82–1.22)

0.99 (0.89–1.09)

Current vs never

1.57 (1.18–2.08)

1.92 (1.67–2.22)

Former vs never

0.85 (0.57–1.25)

1.14 (0.97–1.35)

Smoking
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Hepatitis C virus infection
Positive vs negative

1.40 (1.16–1.70)

1.26 (1.12–1.42)

Never tested vs negative

2.80 (1.99– 3.94)

1.85 (1.68–2.05)

Renal disease, mL/min per 1.73 m2
eGFR <60 vs ≥60
BMI, 5 kg/m

2

0.81 (0.59–1.10)

1.00 (0.86–1.17)

1.12 (1.02–1.23)

1.06 (1.02–1.10)

Anemia, g/dL
Hemoglobin 12–13.9 vs ≥14

1.46 (1.22–1.76)

1.13 (1.02–1.26)

Hemoglobin 10–11.9 vs ≥14

1.60 (1.20–2.14)

1.42 (1.16–1.74)

Hemoglobin <10 vs ≥14

1.83 (1.05–3.19)

1.73 (1.12–2.69)

History of alcohol abuse

1.40 (1.12–1.76)

1.76 (1.58–1.97)

History of cocaine abuse

0.89 (0.69–1.15)

0.88 (0.77–1.01)

Chronic obstructive
pulmonary disease

1.35 (1.07–1.69)

1.32 (1.19–1.47)

QT prolongation medication

0.88 (0.73–1.05)

1.04 (0.95–1.13)

200–499 vs ≥500

1.03 (0.86–1.24)

…

<200 vs ≥500

1.33 (1.04–1.71)

…

1.73 (1.43–2.09)

…

0.77 (0.61–0.96)

…

CD4 cell count, mm

HIV viral load, copies/mL
≥500 vs <500
Antiretroviral therapy
Nucleoside reverse
transcriptase
inhibitor+protease inhibitor
vs no therapy

(Continued)

is associated with low CD4 cell counts and biomarkers
of inflammation in humans27 and depletion of T regulatory cells in murine models.28 The increased risk of
SCD among those with sustained elevation in viremia
and low CD4 cell counts is also consistent with earlier reports examining HIV infection and other cardiovascular diseases.1,3,5,17 Prior studies show that high
viral loads and immunodeficiency increase the levels
of inflammation,29 monocyte activation,30,31 and altered coagulation,6 which, in turn, are associated with
an increased risk of incident cardiovascular disease,
and is itself a major risk factor for SCD in the general
population.10
Our findings have important implications for PLWH
and people without HIV and their providers. First, for
PLWH, viral load suppression may reduce risk of sudden death. We did not observe an excess risk of WHO-
defined SCD among veterans with HIV when CD4
counts were >500 cells/mm3 or viral load remained
<500 copies/mL in time-updated analyses. By the end
of this study, nearly 3 of 4 veterans with HIV were taking antiretroviral therapy within 6 months of their date
of death or last follow-up. Our findings are consistent
with trials reporting that viral suppression lowers the
risk of future non-AIDS outcomes, including cardiovascular disease.32,33 Second, for both PLWH and people without HIV infection, preventing or appropriately
managing SCD risk factors could have a profound impact on SCD risk. This is consistent with earlier work
by Althoff et al,34 who reported that a substantial portion of non-AIDS diseases (eg, cancer, renal disease,
and myocardial infarctions) could be prevented with
interventions on traditional risk factors. Additionally,
if confirmed in other studies, targeting hepatitis C infection and hazardous alcohol consumption may also
reduce the risk of sudden death among PLWH. The
significance of anemia and the risk of SCD in this study
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Figure 3. Sudden cardiac death (SCD) risk among people living with HIV (PLWH) and veterans without HIV by number of
SCD risk factors.
A, Among PLWH and (B) among those without HIV. SCD risk factors: prevalent cardiovascular disease, hypertension, current smoking,
hepatitis C infection, anemia, alcohol use disorder, chronic obstructive pulmonary disease. Incidence rates and hazard ratios (HRs)
were adjusted for age, sex, race/ethnicity, CD4 cell count (PLWH only) and HIV viral load (PLWH only).
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remains unclear. However, anemia increases risk for
myocardial ischemia and our prior work shows that
anemia in PLWH is significantly associated with biomarkers of inflammation, monocyte activation, and altered coagulation.35 While there are no risk prediction
tools for SCD among PLWH, identifying patients with
a high burden of SCD risk factors (Table 4, Figure 3)
may help risk stratify patients at risk for SCD. Future
studies could focus on a risk prediction tool as well as
the underlying mechanism(s) for this excess SCD risk.
Our investigation also has limitations that warrant
discussion. First, our study does not have autopsy
data, which is the gold standard for adjudication of
conventionally defined SCD. As such we do not know
the exact cause of death, which is especially important as nearly half of WHO-defined SCDs may not be
cardiac.10 Moreover, as compared with the general
population, HIV-related causes and occult drug overdose are more common among PLWH, which could
result in a differential misclassification of SCD and by
extension a higher risk of WHO-defined SCD among
PLWH.36 However, one of the major strengths of our
approach was the review of participants’ charts for
any HIV-related diseases (eg, pneumocystis pneumonia) that occurred within 1 year of the date of death,
and a comparator group without HIV infection that was
behaviorally similar to our group of veterans with HIV.
By comparing veterans who had HIV with veterans
without HIV who have similar rates of smoking, alcohol use disorder, cocaine use disorder, and opioid use,
we reduced the possibility of differential misclassification of SCD by HIV status in this study.37 Second,
we acknowledge that some bias may have occurred
by evaluating PLWH who had underlying cause of
death as HIV/AIDS and a CVD cause of death in the

first position for SCD. However, after consultation with
HIV disease experts, we concluded that there was a
larger concern for bias if we excluded these deaths
without review. More specifically, there was a concern that physicians, particularly in the early 2000s,
would state an HIV cause of death in the underlying
position even when that was not the actual cause of
death. Third, we were not able to contact next of kin to
gain additional information about symptoms or factors
immediately associated with the time of death; therefore, the timeline of suddenness could not be verified.
Fourth, while we had access to the entire VA electronic
medical record and non-VA administrative data from
Medicare, Medicaid, and VA fee-for-service files, we
were not able to review detailed clinical notes outside
the VA that were not incorporated into the VA electronic
medical record. Fifth, these data do not suggest that
the recommendations for implantable cardioverter-
defibrillator placement be different for PLWH than in
the general population. Sixth, the participants of our
study have a higher prevalence of cigarette smoking
than the general US population, which may limit the
generalizability of our results. However, in a sensitivity
analysis limited to never-smokers, our primary results
held. Last, as our sample included an overwhelming
number of men, our findings may not be generalizable
to women. Additional studies among PLWH including a
larger proportion of women are needed to further elucidate this association in women.

CONCLUSIONS
HIV infection is associated with an increased risk of
WHO-
defined SCD. This risk was present among
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those with poor HIV disease control and/or a high burden of SCD risk factors but not among those with viral
suppression or high CD4 cell counts. Traditional cardiovascular disease risk factors, hepatitis C infection,
anemia, alcohol use disorder, and chronic obstructive
lung disease were all associated with an increased risk
of SCD. Our data suggest that treating HIV infection
and the associated risk factors for SCD could reduce
SCD risk among PLWH. Future studies should examine the underlying mechanisms for SCD among PLWH.
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Data S1. Steps to adjudicate SCD in our data.
Step 1: There were 27,087 deaths in the VACS. To be included as a SCD event, all participants
had to have a cardiovascular disease cause of death in the underlying position on the death
certificate. The only exception to this rule was for Veterans with HIV who had an HIV/AIDS
cause of death in the underlying position and a cardiovascular disease cause in the first position
on the death certificate. We included this latter provision, because we were concerned that
providers, particularly early on in the highly active antiretroviral therapy era, may have listed an
HIV/AIDS cause of death as the underlying cause even when a cardiac cause was the actual
cause of death.
Once participants were identified with a cardiovascular disease cause of death, then a
series of exclusion criteria were implemented to ensure that the death was not due to a non-SCD
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cause. For this process, we again reviewed the death certificate and determined a person could
not have died of SCD if there was any mention of accident, suicide, homicide, or overdose in any
position on the death certificate. These latter deaths were excluded because they do not meet the
WHO definition of “unexpected death.”
Step 2: After reviewing death certificates, we examined administrative data on the remaining
13,716 death events to ensure that the death occurred outside of the hospital, nursing home,
hospice, or ED with an order to admit. Lastly, consistent with prior studies, SCD events were
excluded among those who had end-stage renal disease and were on hemodialysis.(10)
Step 3: After reviewing the administrative data, we manually reviewed the VA EMR of the
remaining death events (n=9,696) to identify deaths that may have been attributed to cancer, endstage lung disease, AIDS, were listed as Do Not Resuscitate/Do Not Intubate (DNR/DNI), or had

specific/significant recent onset of complaints within one month prior to death (e.g., died at
home soon after undergoing coronary artery bypass graft and mitral valve replacement surgery)
or debilitating new diagnosis within one year of death (e.g., had ischemic stroke followed by two
months of rehabilitation and then died after being discharged to home).
Step 4: Among the 3,383 deaths that remained after manual chart review, we further excluded
any deaths if the participant was hospitalized outside the VA within one month of death based on
a review of Medicare, Medicaid, and VA fee-for-service administrative data. Among those
remaining after these exclusion criteria (n=3,100 deaths), we further excluded deaths for those
participants who had missing follow-up time (48 events), events among those who seroconverted
during follow-up (2 events), and events among Veterans without HIV with measured CD4 or
HIV viral load leading to uncertainty regarding HIV status (15 events). After all exclusions, we
retained 3,035 SCD events for analysis in this sample.
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Table S1. QT Prolongation Medications.
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Amiodarone
Anagrelide
Arsenic trioxide
Astemizole
Azithromycin
Bepridil
Chloroquine
Chlorpromazine
Cilostazol
Ciprofloxacin
Cisapride
Citalopram
Clarithromycin
Cocaine
Disopyramide
Dofetilide
Domperidone
Donepezil
Dronedarone
Droperidol
Erythromycin
Escitalopram
Flecainide
Fluconazole
Gatifloxacin
Grepafloxacin
Halofantrine

Haloperidol
Ibutilide
Levofloxacin
Levomepromazine
Levomethadyl acetate
Mesoridazine
Methadone
Moxifloxacin
Ondansetron
Oxaliplatin
Papaverine HCl
Pentamidine
Pimozide
Probucol
Procainamide
Propofol
Quinidine
Roxithromycin
Sevoflurane
Sotalol
Sparfloxacin
Sulpiride
Sultopride
Terfenadine
Thioridazine
Vandetanib

